Results 11 to 20 of about 1,590 (205)

NRAS, NRAS, Which Mutation Is Fairest of Them All? [PDF]

Journal of Investigative Dermatology, 2016
In 28% of melanomas, NRAS is mutated in one of two hotspots: G12 or Q61. Phosphoproteomic analysis of primary human melanocytes transduced with G12 and Q61 showed different phosphorylation events in the phosphoinositide 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) pathways.
Grill, Christine, Larue, Lionel
openaire   +2 more sources

BRAF, NRAS, KIT, TERT, GNAQ/GNA11 Mutation Profile and Histomorphological Analysis of Anorectal Melanomas: A Clinicopathologic Study

Türk Patoloji Dergisi, 2023
Objective: Primary anorectal melanomas (AMs) are uncommon neoplasms with aggressive behavior. Molecular profile and clinicopathologic features of AMs are still not well established.
Orhun Cig TASKIN, Sule OZTURK SARI, Ismail YILMAZ, Ozge HURDOGAN, Metin KESKIN, Nesimi BUYUKBABANI, Mine GULLUOGLU   +6 more
doaj   +1 more source

NRas activity is regulated by dynamic interactions with nanoscale signaling clusters at the plasma membrane

iScience, 2022
Summary: NRas is a key mediator of the mitogenic pathway in normal cells and in cancer cells. Its dynamics and nanoscale organization at the plasma membrane (PM) facilitate its signaling.
Oren Yakovian, Julia Sajman, Michal Alon, Rand Arafeh, Yardena Samuels, Eilon Sherman   +5 more
doaj   +1 more source

KRAS, NRAS, BRAF, HER2 and microsatellite instability in metastatic colorectal cancer – practical implications for the clinician

Radiology and Oncology, 2019
Colorectal cancer is a successful model of genetic biomarker development in oncology. Currently, several predictive or prognostic genetic alterations have been identified and are used in clinical practice.
Afrăsânie Vlad-Adrian, Marinca Mihai Vasile, Alexa-Stratulat Teodora, Gafton Bogdan, Păduraru Marius, Adavidoaiei Anca Maria, Miron Lucian, Rusu Cristina   +7 more
doaj   +1 more source

The combination of mutations in BRAF and NRAS genes within a one tumor in patients with cutaneous melanoma

Бюллетень сибирской медицины, 2019
The paper provides a clinical description and analysis of two melanoma cases with mutations in the BRAF and NRAS gene within one tumor. Until recently, it was believed that mutations in the BRAF and NRAS genes are exclusive and do not occur within the ...
M. B. Aksenenko, A. S. Averchuk, T. G. Ruksha   +2 more
doaj   +1 more source

KRAS/NRAS Mutations Associated with Distant Metastasis and BRAF/PIK3CA Mutations Associated with Poor Tumor Differentiation in Colorectal Cancer

International Journal of General Medicine, 2023
Juanzi Zeng,1,2 Wenwei Fan,3 Jiaquan Li,1,2 Guowu Wu,1,2 Heming Wu2 1Department of Medical Oncology, Meizhou People’s Hospital, Meizhou Academy of Medical Sciences, Meizhou, People’s Republic of China; 2Center for Precision Medicine, Meizhou People’s ...
Zeng J, Fan W, Li J, Wu G, Wu H
doaj  

PROGNOSTIC SIGNIFICANCE OF NRAS GENE MUTATIONS IN CHILDREN WITH ACUTE MYELOGENOUS LEUKEMIA

Mediterranean Journal of Hematology and Infectious Diseases, 2011
Background: NRAS mutations are the most commonly detected molecular abnormalities  in hematologic malignancies, especially in those of myeloid origin.
Rabab Aly, Mohamed R. El-sharnoby, Adel A. Hagag   +2 more
doaj   +3 more sources

MicroRNA-708 emerges as a potential candidate to target undruggable NRAS.

PLoS ONE, 2023
RAS, the most frequently mutated oncogene that drives tumorigenesis by promoting cell proliferation, survival, and motility, has been perceived as undruggable for the past three decades.
Jia Meng Pang, Po-Chen Chien, Ming-Chien Kao, Pei-Yun Chiu, Pin-Xu Chen, Yu-Ling Hsu, Chengyang Liu, Xiaowei Liang, Kai-Ti Lin   +8 more
doaj   +1 more source

Correlation between KRAS, NRAS and BRAF mutations and tumor localizations in patients with primary and metastatic colorectal cancer

Archives of Medical Science, 2021
Introduction Detection of abnormalities in the KRAS, NRAS and BRAF genes is extremely important for proper qualification of colorectal cancer (CRC) patients for therapy with anti-EGFR (epidermal growth factor receptor) monoclonal antibodies.
Aleksandra Bożyk, Paweł Krawczyk, Katarzyna Reszka, Kinga Krukowska, Agnieszka Kolak, Sławomir Mańdziuk, Kamila Wojas-Krawczyk, Rodryg Ramlau, Janusz Milanowski   +8 more
doaj   +1 more source

The frequency of NRAS mutation in stool samples of Iranian colorectal cancers compared to Finnish patients

Journal of Research in Medical Sciences
Background: Stools from colorectal cancer patients are noninvasive samples that could be used to compare the frequency of hotspot mutations between two different ethnic cohorts.
Farideh Saberi, Omar Youssef, Arto Kokkola, Mahsa Khodadoostan, Pauli Puolakkainen, Rasoul Salehi, Sakari Knuutila   +6 more
doaj   +1 more source